Onkologie. 2023:17(1):70-71 | DOI: 10.36290/xon.2023.016
Clear-cell renal cell carcinoma with sarcomatoid dedifferentiation treated with immunotherapy
- Onkologická klinika, Fakultní nemocnice Olomouc
Sarcomatoid renal cell carcinoma occurs rarely. It is characterized by a very poor prognosis and a low response to treatment with tyrosine kinase inhibitors. Combination of the checkpoint inhibitors ipilimumab and nivolumab is becoming a new standard of treatment. The case report presents a patient with clear-cell renal cell carcinoma with sarcomatoid dedifferentiation that was already generalized at presentation and had a poor prognosis. The patient was treated with the combination of ipilimumab and nivolumab, resulting in a good clinical response, a radiological response in the form of disease stabilization, and a survival of more than two years.
Keywords: renal cell carcinoma, sarcomatoid dedifferentiation, immunotherapy, checkpoint inhibitors.
Accepted: February 22, 2023; Published: March 1, 2023 Show citation
References
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209-249.
Go to original source... 
Go to PubMed... - Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2016;70:93-105. Go to original source... Go to PubMed...
- Kawakami F, Sircar K, Rodriguez-Canales J, et al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017;123:4823-4831. Go to original source... Go to PubMed...
- Gupta S, Cheville JC, Jungbluth AA, et al. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: Implications for clinical management. Mod. Pathol. 2019;32:1344-1358. Go to original source... Go to PubMed...
- Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin. Cancer Res. 2021;27:78-86. Go to original source... Go to PubMed...
- Motzer RJ, Nizar M. Tannir DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine [online]. 2018;378(14):1277-1290 [cit. 2022-11-20]. Available from: doi:10.1056/NEJMoa1712126. Go to original source... Go to PubMed...
- Iacovelli R, Ciccarese C, Bria E, et al. Patients with sarcomatoid renal cell carcinoma-Re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur. J. Cancer. 2020;136:195-203. Go to original source... Go to PubMed...